Articles On Telix Pharmaceuticals (ASX:TLX)

With interest rates almost guaranteed to head upwards this year, multiple experts are emphasising profitability, or at least positive cash flow, as essential for investment. “As interest rates rise, if you don’t have any profit or cash fl...

Australian shares inched to a fresh nine-week high as strengthening commodity prices helped the market weather overseas weakness ahead of tonight’s meeting of US and European leaders. Miners and oil producers advanced as the S&P/ASX...

MELBOURNE, Australia, March 23, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has made significant progress in advancing the Company’s glioblastoma multiforme (GBM) therapy candidate TLX101 in...

The share market rallied to a two-month closing high, bolstered by rising commodity prices and the prospect of record-low rates for some time to come. Strong gains in BHP, Rio Tinto and Newcrest helped lift the S&P/ASX 200 63 points...

Telix Pharmaceuticals (TLX) provides an update regarding the development of its radiopharmaceutical production facility in Belgium The facility will serve as the primary European manufacturing site for Telix’s products and will play an imp...

Australia’s strength in natural resources fired the share market to a two-month high despite declines on Wall Street as investors fretted about soaring inflation. The S&P/ASX 200 surged 89 points or 1.22 per cent to 7367 by mid-sessi...

Highlights The benchmark ASX 200 was up 0.76% to 7,347.7 in the first 15 minutes of trading. US stocks took a U-turn on Monday, after rallying for four straight sessions. The energy and materials sectors were roaring today with gains...

22 Mar 2022 - A snapshot of the stocks on the move featuring New Hope (ASX:NHC), Telix Pharmaceuticals (ASX:TLX) & Bubs Australia (ASX:BUB).

A third day of gains lifted the share market to its highest close in a month as a rebound in commodity prices boosted mining and energy companies. The S&P/ASX 200 rallied 44 points or 0.6 per cent to 7294. The index closed less than...

Telix (ASX:TLX) has announced that its ZIRCON Phase 3 study of investigational kidney cancer imaging agent, TLX250-CDx, has dosed the target enrolment of 252 patients.

The S&P/ASX 200 (ASX: XJO) delivered another positive day despite the incredibly negative backdrop with issues ranging from inflation to commodity price uncertainty and the Ukraine invasion. The market finished 1% higher with the techno...

Today, the S&P/ASX 200 Index (ASX: XJO) reclaimed the 7,000 point level, bucking the trend set on Wall Street last night. At the end of the session, the benchmark index finished 1.04% higher at 7,053 points. Aussie shares broke throug...

The Mesoblast Limited (ASX: MSB) share price has been regaining some of its recent losses today. In afternoon trade, shares in the regenerative medicines company are fetching $1.20, up 16.5%. Despite the gain, shareholders are still a dis...

Telix Pharmaceuticals (TLX) completes target enrolment for its phase III ZIRCON study in patients with kidney cancer A total of 252 patients have now been dosed with TLX250-CDx with the aim of the study to determine the sensitivity and spe...

The ASX 200 Health Index (XHJ) is trading higher by 1.90% at the time of writing, compared to the broader index which is down by 0.30%. Oncology specialist Telix Pharmaceuticals (ASX: TLX) announced that its ZIRCON Phase 3 kidney cancer stu...

08 Mar 2022 - A snapshot of the stocks on the move, featuring Home Consortium (ASX:HMC), Telix Pharmaceuticals (ASX:TLX) & Calix (ASX:CXL).

SYDNEY, March 3, 2022 /PRNewswire/ — Boutique investment and advisory firm Magnolia Capital has released its CY 2021 data that confirms its Magnolia Capital Emerging Companies Microcap Fund 1 ("the Fund") was the highest-performing microcap...

President Biden delivered his annual State of the Union address during the session, with strong commentary around Ukraine and targeted investment into domestic manufacturing capacity supporting US futures and ultimately pushing the S&P/...

Highlights  The ASX 200 closed 0.3% higher, up 20.2 points to 7116.7 with most sectors lower aside from mining and energy stocks. Geopolitical tensions escalated as Russia further advanced its invasion of Ukraine. Crude oil prices sur...

The major miners dug the share market out of a hole after soaring commodity prices helped drive Wall Street sharply lower overnight. The S&P/ASX 200 fell 55 points in early action before a commodities-led rebound. The Australian benc...

02 Mar 2022 - A snapshot of the stocks on the move featuring Mineral Resources (ASX:MIN), Transurban (ASX:TCL) & Telix Pharmaceuticals (ASX:TLX).

Australia’s status as a commodities world-leader helped shield it from pressure on financial markets as surging commodity prices sharpened inflationary worries. Gains in miners and oil producers helped the S&P/ASX 200 advance 16 poin...

Highlights The benchmark ASX 200 index fell 0.68% to 7,047 in the first 15 minutes of morning trade. Brent crude oil surged past US$107 per barrel on Tuesday. The market is having a bearish tilt today with nine out of the 11 sectors t...

Today, the S&P/ASX 200 Index (ASX: XJO) avoided negative territory after its worst fall in 17 months yesterday. At the end of the session, the benchmark index finished 0.1% higher at 6,997.8 points. Investors were torn in two directio...

The share market closed out its worst week since 2020 with a modest rebound as fighting in Ukraine and weak US futures capped risk appetite. An early relief rally mostly petered out as investors awaited evidence the worst of the Ukraine...

A massive overnight reversal on Wall Street and a strong trading update from Afterpay’s US parent company helped the share market pare its losses for the week. The S&P/ASX 200 rallied 16 points or 0.23 per cent as bargain-hunters too...

The share market tumbled 3 per cent to its heaviest loss of the year after Russian troops attacked Ukraine. Oil and gold spiked after explosions were reported in major Ukrainian cities, including the capital, Kiev. Dow futures slumped 62...

The share market slumped 2.5 per cent towards its second-heaviest loss of the year after the Dow closed on the edge of a correction overnight. The S&P/ASX 200 dived 182 points or 2.52 per cent by mid-session. A final loss on that sca...

ShareCafeBuying Opportunities Beckon Amid Biotech Bloodbath The sharp retreat in global biotech valuations is creating rare buying opportunities as investors flee ‘riskier’ sectors on the back of rising interest rates, dwindling liquidity a...

Seven more capital raises were announced today, adding to the 89 ASX-listed companies that have raised almost $2 billion so far this year — that’s an average raise of $22 million. By far, the largest capital raise of 2022 to date was the...

Telix (ASX:TLX) had announced a commercial distribution agreement with Global Medical Solutions Australia for its prostate cancer imaging product Illuccix in the Australian market.

Telix Pharmaceuticals (TLX) enters into an agreement for the commercial distribution of its prostate cancer imaging product Illuccix in Australia The agreement with Global Medical Solutions Australia (GMSA) will see Telix’s product become...

At the time of writing, the ASX 200 Health Index (XHJ) is up by over 4%, while the benchmark ASX 200 is rising by 0.5%. Blood products giant CSL (ASX:CSL) delivered a 5% jump in revenue for the first half, but its net profit slid by 5%. Rev...

Telix Pharmaceuticals (ASX:TLX) has announced a global clinical supply agreement with Berlin-based Eckert & Ziegler Strahlen-und Medizintechnik AG.

The ASX is hosting a goodbye party for Sydney Airport (ASX: SYD) on Wednesday as investors scramble to swap shares in the iconic travel stock one last time. Today, the Supreme Court of New South Wales granted the final approval needed for...

Telix Pharmaceuticals (TLX) is granted an extension for its European regulatory review The notification came from the Danish Medicines Agency, which granted Telix a review period extension of over four months for the company’s application...

Medical imaging software Resonance Health (ASX:RHT) has received the green light in the US for its LiverSmart medical device, making it eligible for recognition by the US government agencies and private insurers. Resonance received confirma...

Today, the S&P/ASX 200 Index (ASX: XJO) has further solidified its position above 7,000 points after going back-to-back with another green day. At the end of the session, the benchmark index finished 1.17% higher at 7,087.7 points. Mo...

Telix Pharmaceuticals (ASX:TLX) has entered an exclusive commercial distribution agreement with Athens-based BIOKOSMOS for its prostate cancer investigational imaging product Illuccix.

Today, the S&P/ASX 200 Index (ASX: XJO) was unable to reclaim lost ground throughout the day. At the end of the session, the benchmark index was 0.24% lower at 6,971.6 points. The overall market ended lower despite the majority of com...

ShareCafeWebinar Recap – LKE, TLX, EMH, ADV Catch up on the full webinar with presentations from Lake Resources (ASX: LKE), Telix Pharmaceuticals (ASX: TLX),  European Metals (ASX: EMH)  & Ardiden Limited (ADV) Webinar Recap...

ShareCafeTelix Pharmaceuticals (ASX: TLX) – Webinar Presentation Dr Christian Behrenbruch – CEO & Managing Director – Telix is a late-stage radiopharmaceutical company developing diagnostic and therapeutic assets using Molecularly Targ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. During his Australian Open quar...

Australian medical device company and global supplier of rapid diagnostic testing devices (RDT), Atomo (ASX: AT1) has scored distribution rights for rapid antigen tests in New Zealand, after being authorised by the New Zealand Ministry of H...

Telix Pharmaceuticals (ASX:TLX) has announced that the first patient has been dosed in its prostate-specific membrane antigen targeting ‘ProstACT’ therapeutic program.

Telix Pharmaceuticals (TLX) has first patient dosed in its prostate-specific membrane antigen Telix’s ProstACT study program is evaluating the efficacy of Telix’s lutetium-177 (177Lu)-labelled therapeutic antibodies in all stages of prosta...

Telix Pharmaceuticals (ASX:TLX) has raised $175 million it says will be used to fund the progression of its promising pipeline.

Fears of a market meltdown subsided early today as the ASX 200 fell by just 0.5%, lifted by the bounce back in US stock futures in Asian trading. A rush of US earnings reports in the next few days, along with the two-day Federal Reserve mee...

Key points The Telix Pharmaceuticals share price is down 13% on Monday The company’s December quarterly report revealed a 51% fall in cash reserves It is also conducting a $175 million capital raise The Telix Pharmaceuticals (ASX: TLX...

In afternoon trade on Monday, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decline. At the time of writing, the benchmark index is down 0.4% to 7,146.3 points. Four ASX shares that are falling more than most t...